This study will be conducted on women of reproductive age diagnosed with idiopathic overactive bladder who either do not want to use drug treatment or cannot tolerate it due to side effects. Our aim is to examine the effects of a treatment method called transcutaneous tibial nerve stimulation on overactive bladder symptoms, urine flow measurements (uroflowmetry), post-voiding residue, pelvic floor muscle activity, heart rate variability, and quality of life in these individuals.
Age range
18 Years – 50 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incontinence Impact Questionnaire scale
Timeframe: From enrollment to the end of treatment at 6 weeks
Overactive bladder validation score 8
Timeframe: From enrollment to the end of treatment at 6 weeks
Voiding volume
Timeframe: From enrollment to the end of treatment at 6 weeks
Voiding time
Timeframe: From enrollment to the end of treatment at 6 weeks
Maximum flow rate
Timeframe: From enrollment to the end of treatment at 6 weeks
Time to reach maximum flow
Timeframe: From enrollment to the end of treatment at 6 weeks
Average flow rate
Timeframe: From enrollment to the end of treatment at 6 weeks
Post-voiding residual urine
Timeframe: From enrollment to the end of treatment at 6 weeks
SDNN (msn)
Timeframe: From enrollment to the end of treatment at 6 weeks
RMSSD (msn)
Timeframe: From enrollment to the end of treatment at 6 weeks
pNN50 (%)
Timeframe: From enrollment to the end of treatment at 6 weeks
TP (msn²)
Timeframe: From enrollment to the end of treatment at 6 weeks
LF (msn²), %LF, LFnorm
Timeframe: From enrollment to the end of treatment at 6 weeks
HF (msn²), %HF, HFnorm
Timeframe: From enrollment to the end of treatment at 6 weeks
LF/HF (msn²)
Timeframe: From enrollment to the end of treatment at 6 weeks
Pelvic Floor Muscle-Contraction average (μV)
Timeframe: From enrollment to the end of treatment at 6 weeks
Pelvic floor muscle contraction MVC (%)
Timeframe: From enrollment to the end of treatment at 6 weeks
Pelvic floor muscle relaxation mean (μV)
Timeframe: From enrollment to the end of treatment at 6 weeks
Pelvic floor muscle relaxation MVC (%)
Timeframe: From enrollment to the end of treatment at 6 weeks
Pelvic floor muscle contraction onset (s)
Timeframe: From enrollment to the end of treatment at 6 weeks